基于多酸的纳米颗粒用于增强向和控制甲释放的肺炎治疗
Cong Li1, Jing Li2, Yujie Bai2
1School of Pharmaceutical Science, Liaoning University, Shenyang 110036, China; Liaoning Key Laboratory for New Drug Development, Shenyang 110036, China.
International journal of biological macromolecules
|January 8, 2025
概括
这项研究开发了一种新型的纳米粒子系统,用于针对性地输送德甲来治疗急性肺损伤 (ALI) 和急性呼吸困扰综合征 (ARDS). 该系统有效地向炎症性M1巨细胞,减少肺炎.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 肺部医学 肺部医学
背景情况:
- 急性肺损伤 (ALI) 和急性呼吸困难综合征 (ARDS) 是具有显著炎症和呼吸衰竭的危急情况.
- 目前针对ALI/ARDS的德克萨米他 (Dex) 治疗方法面临着可溶性差和全身副作用等挑战.
- 需要先进的药物输送系统,用于肺部疾病的向治疗.
研究的目的:
- 开发一种创新的纳米颗粒输送系统,用于针对性地向ALI/ARDS患者的炎症肺组织输送德甲.
- 为了增强药物封装和稳定性,使用新型 taurine-Vitamin E 苏酸两性分子.
- 为了利用聚酸 (PSA) 专门准M1巨细胞,这是ALI/ARDS中的关键炎症细胞.
主要方法:
- 通过静电组件制造基多 (CS) 和聚酸 (PSA) 纳米粒子系统.
- 合成氨酸-维生素E酸两性分子 (TVES和TGVES),以改善药物负载和稳定性.
- 在体外评估M1巨的向性和在体内评估ALI/ARDS模型中的抗炎作用.
主要成果:
- CS-PSA纳米粒子系统在体外有效向M1巨细胞.
- 在体内研究显示,在纳米粒子系统治疗后,肺炎的显著减少.
- 合成的两性分子增强了纳米颗粒中的药物封装和稳定性.
结论:
- 开发的CS-PSA纳米粒子平台为ALI/ARDS中向性肺部药物输送提供了一个有前途的战略.
- 这种有针对性的方法有可能提高治疗疗效,并减少德克萨米他的全身副作用.
- 这项研究突出了功能添加剂的潜力,如氨酸在先进的纳米医学中治疗炎症性疾病.
相关概念视频
01:22Drug Delivery: Miscellaneous Routes
309
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
309
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
217
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
217
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
01:23Inhaled Medications
237
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
237
01:17Drugs Used in Lower Respiratory Disorders: Overview
349
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
349